These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24918318)

  • 21. The safety of infliximab infusions in the community setting.
    Ducharme J; Pelletier C; Zacharias R
    Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.
    Denadai R; Teixeira FV; Steinwurz F; Romiti R; Saad-Hossne R
    J Crohns Colitis; 2013 Aug; 7(7):517-24. PubMed ID: 22960136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.
    Hämäläinen A; Lahdenne P; Wikström A; Aalto K; Kolho KL
    Clin Exp Rheumatol; 2012; 30(4):590-1. PubMed ID: 22766212
    [No Abstract]   [Full Text] [Related]  

  • 27. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
    Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
    Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 35. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
    Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
    Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.
    Kolho KL; Ruuska T; Savilahti E
    Acta Paediatr; 2007 Jan; 96(1):128-30. PubMed ID: 17187619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
    Denadai R; Teixeira FV; Saad-Hossne R
    Arq Gastroenterol; 2012; 49(2):172-6. PubMed ID: 22767007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.